CN106581583A - Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof - Google Patents
Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof Download PDFInfo
- Publication number
- CN106581583A CN106581583A CN201611198633.3A CN201611198633A CN106581583A CN 106581583 A CN106581583 A CN 106581583A CN 201611198633 A CN201611198633 A CN 201611198633A CN 106581583 A CN106581583 A CN 106581583A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart failure
- chronic heart
- semen
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 210000000582 semen Anatomy 0.000 claims abstract description 44
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000005303 weighing Methods 0.000 claims abstract description 8
- 235000020374 simple syrup Nutrition 0.000 claims abstract description 7
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 27
- 241000208340 Araliaceae Species 0.000 claims description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 6
- 241000700159 Rattus Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 13
- 206010019280 Heart failures Diseases 0.000 abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 208000004124 rheumatic heart disease Diseases 0.000 abstract description 6
- 208000031229 Cardiomyopathies Diseases 0.000 abstract description 5
- 201000006306 Cor pulmonale Diseases 0.000 abstract description 5
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract description 5
- 208000015210 hypertensive heart disease Diseases 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 241000304531 Allium macrostemon Species 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 238000004064 recycling Methods 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 102000005862 Angiotensin II Human genes 0.000 description 6
- 101800000733 Angiotensin-2 Proteins 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 6
- 229950006323 angiotensin ii Drugs 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- -1 Ang- II Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 238000009636 ATP test Methods 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004490 capsule suspension Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000009912 gualou xiebai baijiutang Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000009810 qiangxin Substances 0.000 description 1
- 239000009869 qiliqiangxin Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treatment of chronic heart failure and a preparation method thereof. The Chinese medicinal composition is composed of the following components by weight: 140-160 parts of ginseng, 180-200 parts of Salvia Miltiorrhiza, 180-200 parts of Allium macrostemon, 240-260 parts of semen lepidii, 240-260 parts of Poria cocos, 180-200 parts of curcuma zedoary, and 180-200 parts of peach kernel. The preparation method includes: weighing the components and adding water for decoction, concentrating the decoction to obtain a concentrated solution; adding ethanol into the concentrated solution to conduct extraction, recovering ethanol from the supernatant recycling ethanol till no alcohol flavor; adding simple syrup into sinking liquid, adjusting the pH value, and performing filtering, thus obtaining the Chinese medicinal composition. The Chinese medicinal composition provided by the invention can significantly improve the chronic heart failure model of rats, has certain treatment effect on chronic heart failure, and can be used for treatment of cardiac insufficiency and chronic cardiac failure caused by coronary heart disease, hypertensive heart disease, rheumatic heart disease, cor pulmonale and cardiomyopathy, etc.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine, specifically, is related to a kind of Chinese medicine of chronic heart failure
Compositionss and preparation method thereof.
Background technology
More and more with old people's ratio, the M ＆ M of cardiovascular and cerebrovascular disease also rises therewith.Mental and physical efforts
Exhaustion is the end stage eventually of various cardiovascular disease such as rheumatic heart disease, cardiomyopathy, coronary heart disease, and which occurs the pathology life of development
Reason basis is myocardial remodelling, with cardiac blood supply deficiency, can not meet body demand as its feature.
More currently used for the Western medicine kind for the treatment of heart failure, though the instant effect persistent period is short, and side effect is larger.
Commercially available QiLi capsule, it is undesirable to there is curative effect, takes the deficiencies such as inconvenience, slowly effect.
The content of the invention
In view of this, the present invention is directed to above-mentioned problem, there is provided a kind of Chinese medicine composition of chronic heart failure
And preparation method thereof, rat chronic Heart Failure Model is can obviously improve, the effect with certain chronic heart failure.
In order to solve above-mentioned technical problem, the invention discloses a kind of Chinese medicine composition of chronic heart failure, presses
It is composed of the following components according to parts by weight：Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis 180-200 parts, Semen Lepidii (Semen Descurainiae) 240-
260 parts, Poria 240-260 parts, Rhizoma Curcumae 180-200 parts, Semen Persicae 180-200 parts.
Preferably, it is composed of the following components according to parts by weight：150 parts of Radix Ginseng, 200 parts of Radix Salviae Miltiorrhizae, 200 parts of Bulbus Allii Macrostemonis, Semen Lepidii
250 parts of son, 250 parts of Poria, 200 parts of Rhizoma Curcumae, 200 parts of Semen Persicae.
The invention also discloses a kind of preparation method of the Chinese medicine composition of chronic heart failure, to prepare 1000ml
Oral liquid meter, comprises the following steps：
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis
180-200 parts, Semen Lepidii (Semen Descurainiae) 240-260 parts, Poria 240-260 parts, 200 parts of Rhizoma Curcumae, 200 parts of Semen Persicae；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 2-3 time, is boiled every time 20-40 minutes by step 2, is filtered to merge and is decocted
Liquid, obtains concentrated solution after concentration；
Step 3, in concentrated solution adds ethanol during room temperature, places more than 24 hours, and supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup in sinking liquid, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing,
Filtration, obtains final product.
Further, the concentration is specially：Relative density 1.15-1.30 is concentrated in 80 DEG C.
Further, it is 60% to add ethanol to make its volume fraction in the step 3.
Further, also include：Canned and sterilizing, the sterilizing are specially 100 DEG C and sterilize 30 minutes.
Compared with prior art, the present invention can be obtained including following technique effect：
The Chinese medicine composition of the chronic heart failure that the present invention is provided, is the choosing on the basis of existing theory of Chinese medical science
It is raw material with Radix Ginseng, Radix Salviae Miltiorrhizae, Bulbus Allii Macrostemonis, Semen Lepidii (Semen Descurainiae), Poria, Rhizoma Curcumae, Semen Persicae, and carries out scientific compatibility, plays which and mutually cooperate with work
With with inrigorating qi and promoting blood circulation, damp eliminating, the work(of invigorating spleen for diuresis, can obviously improve rat chronic Heart Failure Model, with necessarily treating chronic
The effect of heart failure, can be used for treat by coronary heart disease, hypertensive heart disease, rheumatic heart disease, pulmonary heart disease and
Cardiac insufficiency that cardiomyopathy etc. causes, chronic heart failure, and preparation method are simple, are capable of achieving industrialized production.
Certainly, the arbitrary product for implementing the present invention is it is not absolutely required to while reaching all the above technique effect.
Description of the drawings
Accompanying drawing described herein is used for providing a further understanding of the present invention, constitutes the part of the present invention, this
Bright schematic description and description does not constitute inappropriate limitation of the present invention for explaining the present invention.In the accompanying drawings：
Fig. 1 be embodiment of the present invention rat chronic heart failure model heart tissue form, HE X200, wherein：(A) it is
Blank group, is (B) model group, is (C) QiLi capsule group, is (D) heavy dose of group, is (E) middle dose group, is (F) little dose
Amount group.
Specific embodiment
Describe embodiments of the present invention below in conjunction with embodiment in detail, thereby to the present invention how application technology handss
Section come solve technical problem and reach technology effect realize that process can fully understand and implement according to this.
First, the prescription and content of Chinese medicine composition of the invention
The present invention provides a kind of Chinese medicine composition of chronic heart failure, according to parts by weight by following components group
Into：It is composed of the following components according to parts by weight：Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis 180-200 parts, Semen Lepidii
Sub- 240-260 parts, Poria 240-260 parts, Rhizoma Curcumae 180-200 parts, Semen Persicae 180-200 parts.
Preferably, it is composed of the following components according to parts by weight：150 parts of Radix Ginseng, 200 parts of Radix Salviae Miltiorrhizae, 200 parts of Bulbus Allii Macrostemonis, Semen Lepidii
250 parts of son, 250 parts of Poria, 200 parts of Rhizoma Curcumae, 200 parts of Semen Persicae.
The preparation method of above-mentioned Chinese medicine composition, in terms of preparing 1000ml oral liquids, comprises the following steps：
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis
180-200 parts, Semen Lepidii (Semen Descurainiae) 240-260 parts, Poria 240-260 parts, Rhizoma Curcumae 180-200 parts, Semen Persicae 180-200 parts；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 2-3 time, is boiled every time 20-40 minutes by step 2, is filtered and is merged every
Secondary decocting liquid, is concentrated into relative density 1.15-1.30 in 80 DEG C；
Preferably, decoction 3 times, 40 minutes every time, the effective ingredient Hesperidin extracted amount highest extracted under the extraction conditions,
For 112.86 μ g/50g medical materials.
Step 3, adds ethanol during room temperature in concentrated solution, stirring while adding, and it is 60% to make containing amount of alcohol, is placed 24 hours
More than, supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup in sinking liquid, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing,
Filtration, fill, 100 DEG C, sterilizing is obtained final product for 30 minutes.
2nd, each prescription function and indication
1st, the present invention in each component function：
Radix Ginseng：Invigorating vital QI and recuperating the depleted YANG；Radix Salviae Miltiorrhizae：Blood circulation promoting and blood stasis dispelling；Bulbus Allii Macrostemonis：Activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving；Semen Lepidii (Semen Descurainiae)：Detumescence water-filling；Fu
Siberian cocklebur：Invigorating the spleen to clear away damp pathogen diuretic；Rhizoma Curcumae：Promoting the circulation of QI to relieve pain, product eliminating stagnation, removing blood stasis；Semen Persicae：Blood circulation promoting and blood stasis dispelling.
Cure mechanism：Ginseng qi-tonifying recuperating depleted YANG, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling are monarch altogether, Bulbus Allii Macrostemonis activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving, for breast
Numbness pain is minister, and Semen Lepidii (Semen Descurainiae) detumescence water-filling is assistant, Poria invigorating the spleen to clear away damp pathogen diuretic is to make.Rhizoma Curcumae has promoting the circulation of QI to relieve pain, removing blood stasis
Effect, Semen Persicae has blood circulation promoting and blood stasis dispelling effect.Full side follows the combination principle of monarch, with inrigorating qi and promoting blood circulation, damp eliminating diuretic
Work(.For the heart work(that coronary heart disease, hypertensive heart disease, rheumatic heart disease, pulmonary heart disease and cardiomyopathy etc. cause
Can not be complete.According to coronary heart disease " blood stasis due to qi deficiency " pathogenesis, the rule for the treatment of of ancestor's " treating both the principal and secondary aspects of a disease " carries out prescription to we, with the people of strongly invigorating primordial QI
Join as monarch drug, embody " gas to lead to as will ", " blood is with living as expensive " treats rule for the treatment of.Radix Salviae Miltiorrhizae makes the aobvious general's blood of mended strength promote blood circulation
Work(.Qi-regulating is equipped with, the chest stuffiness relieving activates yang, the Bulbus Allii Macrostemonis of eliminating stagnation, mended gas has been depended on and has been delivered, and avoid which
The consumption impairment of YIN blood of the product that pungent-warm perfume (or spice) is altered.With Radix Ginseng, Radix Salviae Miltiorrhizae mutually made to be use, made contributions with Bulbus Allii Macrostemonis mutual reinforcement between, is associated with phase with Semen Lepidii (Semen Descurainiae), Poria
Deq is evident, can greatly enhance the blood circulation promoting and blood stasis dispelling of full side, promote blood circulation and search the power of network.It can be seen that, the party links closely pathogenesis, reasonable recipe, medication
Precise and appropriate, compatibility is rigorous, plays tonifying QI to promote blood circulation, blood circulation promoting and blood stasis dispelling altogether, promotes blood circulation and search network, the chest stuffiness relieving, activates yang, eliminating stagnation, damp eliminating diuretic, invigorating spleen to remove dampness
Work(.Compare with recipe GUALOUXIEBAI TANG and decoction of four noble drugs, have with the wonderful of " work(" different song.
In a word, seven medicines are shared, and function QI invigorating, blood circulation promoting and blood stasis dispelling, qi-regulating, the chest stuffiness relieving are activated yang, eliminating stagnation, invigorating the spleen to clear away damp pathogen.All medicines share
Then inrigorating qi and promoting blood circulation, damp eliminating diuretic, for coronary heart disease, hypertensive heart disease, rheumatic heart disease, pulmonary heart disease and cardiac muscle
The cardiac insufficiency that disease etc. causes.
2nd, indication：With inrigorating qi and promoting blood circulation, damp eliminating, the work(of invigorating spleen for diuresis, for coronary heart disease, hypertensive heart disease,
The cardiac insufficiency that rheumatic heart disease, pulmonary heart disease and cardiomyopathy etc. cause, chronic heart failure etc..
3rd, usage：Orally, 3 times a day, according to degree of heart failure i.e. I, II, III degree apply respectively every time 10mL, 20mL,
30mL。
3rd, pharmacodynamic experiment
1st, laboratory animal：Cleaning grade SD male rats 72, weight 180-220g, male, by Shandong Province's laboratory animal
Center provides, animal quality certification number：37009200000906, credit number：SCXK (Shandong) 2015-0005.
2nd, experimental technique
72 rats, take 12 at random by weight and are only used as blank group, and remaining rat carries out modeling.Rat fills respectively for modeling
(20ml/kg, 10ml/kg, 5ml/kg take Chinese medicine composition to take Chinese medicine composition prepared by the large, medium and small dosage embodiment of the present invention 1
Thing 500ml, 250ml, 125ml constant volume is to 500ml, gavage volume 2ml/100g, equivalent to 20 times of quantity, 10 times, 5
Times), QiLi capsule suspension (0.6ml/kg, 0.3ml, 2ml/100g, equivalent to the 10 of quantity as a control group
Times), QiLi capsule is produced by Shijiazhuang Yiling Pharmaceutical Co., Ltd, lot number A1505008.Model group is gavaged together
ML normal saline (2ml/100g), injects doxorubicin hydrochloride once weekly, (by adriamycin vial normal saline
2mg/mL solution is configured to, by 4mg/kg body weight, i.e. 2mL/kg body weight doses lumbar injection, 1 times a week, totally 6 weeks, accumulation total amount
24mg/kg body weight, normal group inject the normal saline of same volume), it is administered once daily, successive administration 8 weeks.Each group rat is equal
Every morning administration, feed material in afternoon.
3rd, test index
(1) cardiodynamicss change
After 1h after last 1 gavage (water 12h is can't help in fasting), rat 10% chloral hydrate (0.03ml/100g) abdomen
After the injecting anesthetic of chamber, rat is fixed on into rat plate, and on without innovative function detector, after stablizing 2 minutes, records HR, left room
Shrink intrinsic pressure (LVSP), left ventricular end diastolic presssure (LVEDP) etc..
(2) cardiac index
Left room relax, contracting functional examination it is complete after, separation common carotid artery after take blood system from determination of serum serum BNP, IL-6, Ang-
II, CRP, TNF-α, ATP and cTnI；Then take and whole-heartedly weigh, then separate left ventricle (containing interventricular septum) and weigh, calculate whole-heartedly index
(whole-heartedly weight/body weight) and left ventricle index (left ventricular mass/body weight)；The blood in heart is sucked before weighing with absorbent paper.
4th, statistical procedures method
Data analysiss carry out the statistical procedures of data information, measurement data average with the medical statistics bags of SPSS17.0
± standard deviationRepresent, comparing between each group and adopting one factor analysis of variance, the neat person of variance test uses LSD methods, heterogeneity of variance
Person is checked with Games-Howell methods, and ranked data are checked using Ridit.
5th, experimental result
(1) serum Angiotensin II (Ang-II), Type B brain natriuretic peptide (BNP), cardiac muscle troponin I (cTnI), phosphoric acid
Gland glycoside (ATP)：
1 rat chronic Heart Failure Model serum Ang of table-II, BNP, cTnI, ATP test result (x ± s)
Note：* to be represented and compare P with model group<0.01, * to represent and compare P with model group<0.05.
Ang-II is to cause myocardial hypertrophy, remodeling ventricle, and inducing cardiomyocytes apoptosis ultimately results in chronic heart failure
Important and relatively independent, special index.BNP is a kind of peptide hormone of natriuretic peptide class, most in the content of left atrium.
The synthesis secretion of BNP is affected by vascular capacitance load and wall tension, therefore blood BNP contents can directly reflect ventricular function.From
Table 1 can be seen that, with blank group ratio, model group serum Ang-II, BNP, cTnI level significantly rising (P<0.01), ATP levels
(P is significantly reduced<0.01), illustrate to make Chronic heart failure model success.Compared with model group, large, medium and small dosage group is strong with stilbene Li
Heart-soothing capsule group can significantly reduce serum Ang-II, BNP, cTnI level (P<0.01)；Large, medium and small dosage group and Qiliqiangxin
Capsules group can significantly raise ATP level (P<0.01).
(2) serum IL-6 (IL-6), C reactive protein (CRP), and tumor necrosis factor (TNF-a)：
2 rat chronic Heart Failure Model blood serum IL-6 of table, CRP, TNF-a test result
Note：* to be represented and compare P with model group<0.01, * to represent and compare P with model group<0.05.
Blood serum IL-6, the level of TNF-α and the cardiovascular risk factors conditions of patients order of severity are closely related, C reaction eggs
White detection can be further discovered that the faint inflammatory conditions of chronic heart failure early stage.As can be seen from Table 2, compared with blank group,
Model group blood serum IL-6, CRP, TNF-a level significantly raise (P<0.01), illustrate to make Chronic heart failure model success.With model group
Compare, large, medium and small dosage group can significantly reduce serum CA125, TNF-a level (P with QiLi capsule group<0.01)；Greatly,
Middle dose group can significantly reduce IL-6 (P with QiLi capsule group<0.01), small dose group can substantially reduce blood
Clear IL-6 level (P<0.05).
(3) left ventricle index, whole-heartedly index：
3 rat chronic Heart Failure Model left ventricle index of table, whole-heartedly index test result
Note：* to be represented and compare P with model group<0.01, * to represent and compare P with model group<0.05.
As can be seen from Table 3, with blank group ratio, model group left ventricle index, whole-heartedly index significantly raise (P<0.01), say
Bright Chronic heart failure model modeling success.With model group ratio, middle dose group and QiLi capsule group can significantly reduce left ventricle
Index and (P<0.01), large and small dosage group can obviously reduce left ventricle index (P<0.05)；Middle dose group and QiLi capsule
Group can significantly reduce whole-heartedly index (P<0.01), small dose group can obviously reduce whole-heartedly index (P<0.05), heavy dose of group has drop
The trend (P ﹥ 0.05) of low whole-heartedly index.
(4) cardiodynamicss：
4 rat chronic Heart Failure Model cardiodynamicss test result of table (N=12)
Note：* to be represented and compare P with model group<0.01, * to represent and compare P with model group<0.05.
As can be seen from Table 4, compared with blank group, model group heart rate HR, Ejection, Lvsp levels significantly reduce (P
<0.01), mean arterial pressure MAP, heart Lvedp levels are significantly raised, (P<0.01), illustrate to make Chronic heart failure model success.With
Model group is compared, and middle dose group and QiLi capsule group can notable elevated heart rate HR, Ejection, Lvsp level (P<
0.01), large and small dosage group can significantly raised heart rate HR, Lvsp level (P<0.05), small dose group significantly raised can penetrate blood
Fraction EF level (P<0.05), heavy dose of group has the trend (P ﹥ 0.05) for raising Ejection level；Middle dose group and stilbene Li
Qiangxin capsules group can significantly raise heart Lvsp level (P<0.01), large and small dosage group can significantly raised heart Lvsp water
Flat (P<0.05)；Middle dose group and QiLi capsule group can significantly reduce Lvedp level (P<0.01), small dose group is obvious
Reduce Lvedp level (P<0.05), heavy dose of group has the trend (P ﹥ 0.05) for reducing Lvedp levels；Large, medium and small dosage group and
QiLi capsule group can significantly reduce mean arterial pressure MAP level (P<0.01).
(5) heart tissue form：
Each group heart tissue form om observation is visible：Blank group rat heart myocardium cell arrangement is neat, myocardial cell
Normal, interstitial is also normal, referring specifically to Fig. 1 (A)；The arrangement of model group rats cardiac myocytes is less neat, the heart
There is steatosis and focal myocardium cell necrosis, and cell infiltration in myocyte, and nucleus increase, interstitial occur edema and
Cell infiltration, referring specifically to Fig. 1 (B)；The myocardial cell arrangement of the QiLi capsule group rat heart is less neat, myocardial cell
There is focal degeneration, nucleus are more intensive, and interstitial disappears substantially, referring specifically to Fig. 1 (C)；Heavy dose of group rat heart
Myocardial cell arrangement is more neat, and myocardial cell is normal, and interstitial is also normal, referring specifically to Fig. 1 (D)；Middle dose group
The myocardial cell arrangement of the rat heart is more neat, and degeneration occurs in minority myocardial cell, and nucleus are more intensive, and interstitial disappears substantially
Lose, referring specifically to Fig. 1 (E)；The myocardial cell arrangement of the small dose group rat heart is more neat, and degeneration occurs in minority myocardial cell,
Nucleus are more intensive, the visible a small amount of cell infiltration of interstitial, referring specifically to Fig. 1 (F).
In sum, the Chinese medicine composition of chronic heart failure of the invention, can significantly reduce serum Ang-II,
BNP, cTnI, CRP, TNF-a level；Large, medium and small dosage group can significantly raise ATP levels, and big, middle dose group significantly can drop
Low IL-6, small dose group can substantially reduce IL-6；Can significantly raised heart HR levels and Lvsp levels,
Each administration group has the trend for reducing heart Lvedp levels, can significantly reduce left ventricle index, whole-heartedly index and Cardiac Power
Learn, show that said composition has the effect of certain chronic heart failure.The present invention is carried for said composition treatment chronic heart failure
Experimental basis are supplied, has been that certain basis has been established in clinical treatment chronic heart failure.
Embodiment 1
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 150g, Radix Salviae Miltiorrhizae 200g, Bulbus Allii Macrostemonis 200g, Semen Lepidii (Semen Descurainiae)
250g, Poria 250g, Rhizoma Curcumae 200g, Semen Persicae 200g；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 3 times, is boiled every time 40 minutes by step 2, filter merge 3 times decoct
Liquid, is concentrated into relative density 1.20 in 80 DEG C；
Step 3, adds ethanol during room temperature in concentrated solution, stirring while adding, and it is 60% to make containing amount of alcohol, is placed 24 hours
More than, supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing, filters, fill,
100 DEG C of sterilizings are obtained final product for 30 minutes.
Embodiment 2
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 140g, Radix Salviae Miltiorrhizae 180g, Bulbus Allii Macrostemonis 180g, Semen Lepidii (Semen Descurainiae)
240g, Poria 240g, Rhizoma Curcumae 180g, Semen Persicae 180g；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 2 times, is boiled every time 30 minutes by step 2, filter merge 2 times decoct
Liquid, is concentrated into relative density 1.15 in 80 DEG C；
Step 3, adds ethanol during room temperature in concentrated solution, stirring while adding, and it is 60% to make containing amount of alcohol, is placed 24 hours
More than, supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing, filters, fill,
100 DEG C of sterilizings are obtained final product for 30 minutes.
Embodiment 3
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 160g, Radix Salviae Miltiorrhizae 190g, Bulbus Allii Macrostemonis 190g, Semen Lepidii (Semen Descurainiae)
260g, Poria 260g, Rhizoma Curcumae 190g, Semen Persicae 190g；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 3 times, is boiled every time 20 minutes by step 2, filter merge 3 times decoct
Liquid, is concentrated into relative density 1.30 in 80 DEG C；
Step 3, adds ethanol during room temperature in concentrated solution, stirring while adding, and it is 60% to make containing amount of alcohol, is placed 24 hours
More than, supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing, filters, fill,
100 DEG C of sterilizings are obtained final product for 30 minutes.
The present invention provides a kind of method that the Chinese medicine composition is prepared as oral liquid, but restriction can only not adopt this kind of
Prepared by method, do not constitute the restriction to the Chinese medicine composition dosage form and preparation method, other sides well known in the art may also be employed
Method is preparing different dosage forms, the such as common formulations such as ointment, tablet, pill, powder, capsule.
Described above illustrates and describes some preferred embodiments of invention, but as previously mentioned, it should be understood that invention is not
Form disclosed herein is confined to, the exclusion to other embodiment is not to be taken as, and be can be used for various other combinations, modification
And environment, and can be carried out by the technology or knowledge of above-mentioned teaching or association area in invention contemplated scope described herein
Change.And change that those skilled in the art are carried out and change be without departing from the spirit and scope of invention, then all should be in the appended power of invention
In the protection domain that profit is required.
Claims (6)
1. a kind of Chinese medicine composition of chronic heart failure, it is characterised in that composed of the following components according to parts by weight：
Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis 180-200 parts, Semen Lepidii (Semen Descurainiae) 240-260 parts, Poria 240-260 parts, Rhizoma Curcumae
180-200 parts, Semen Persicae 180-200 parts.
2. the Chinese medicine composition of chronic heart failure as claimed in claim 1, it is characterised in that according to parts by weight by
Following components is constituted：150 parts of Radix Ginseng, 200 parts of Radix Salviae Miltiorrhizae, 200 parts of Bulbus Allii Macrostemonis, 250 parts of Semen Lepidii (Semen Descurainiae), 250 parts of Poria, 200 parts of Rhizoma Curcumae, Fructus Persicae
200 parts of core.
3. a kind of preparation method of the Chinese medicine composition of chronic heart failure, it is characterised in that oral to prepare 1000ml
Liquid meter, comprises the following steps：
Step 1, weighs following components respectively according to parts by weight：Radix Ginseng 140-160 parts, Radix Salviae Miltiorrhizae 180-200 parts, Bulbus Allii Macrostemonis 180-
200 parts, Semen Lepidii (Semen Descurainiae) 240-260 parts, Poria 240-260 parts, Rhizoma Curcumae 180-200 parts, Semen Persicae 180-200 parts；
The above-mentioned each component for weighing is added 8 times of decoctings to boil 2-3 time, is boiled every time 20-40 minutes by step 2, filters collecting decoction,
Concentrated solution is obtained after concentration；
Step 3, in concentrated solution adds ethanol during room temperature, places more than 24 hours, and supernatant reclaims ethanol to without alcohol taste；
Step 4, adds simple syrup in sinking liquid, adjusts pH value to 5.0-7.0, adds water to 1000ml, stir evenly standing, filters
Cross, obtain final product.
4. the preparation method of the Chinese medicine composition of chronic heart failure as claimed in claim 3, it is characterised in that described
Concentration is specially：Relative density 1.15-1.30 is concentrated in 80 DEG C.
5. the preparation method of the Chinese medicine composition of chronic heart failure as claimed in claim 3, it is characterised in that described
It is 60% to add ethanol to make its volume fraction in step 3.
6. the preparation method of the Chinese medicine composition of chronic heart failure as claimed in claim 3, it is characterised in that also wrap
Include：Canned and sterilizing, the sterilizing are specially 100 DEG C and sterilize 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611198633.3A CN106581583A (en) | 2016-12-22 | 2016-12-22 | Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611198633.3A CN106581583A (en) | 2016-12-22 | 2016-12-22 | Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581583A true CN106581583A (en) | 2017-04-26 |
Family
ID=58600694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611198633.3A Pending CN106581583A (en) | 2016-12-22 | 2016-12-22 | Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581583A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108815431A (en) * | 2018-08-15 | 2018-11-16 | 中国人民解放军第三〇七医院 | A kind of Chinese materia medica preparation and preparation method thereof for treating coronary heart disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670934A (en) * | 2012-05-11 | 2012-09-19 | 中国人民解放军第一五二中心医院 | Traditional Chinese medicine preparation for treating chronic heart failure |
-
2016
- 2016-12-22 CN CN201611198633.3A patent/CN106581583A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670934A (en) * | 2012-05-11 | 2012-09-19 | 中国人民解放军第一五二中心医院 | Traditional Chinese medicine preparation for treating chronic heart failure |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108815431A (en) * | 2018-08-15 | 2018-11-16 | 中国人民解放军第三〇七医院 | A kind of Chinese materia medica preparation and preparation method thereof for treating coronary heart disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN101890125A (en) | Medicament for treating hyperthyroidism and preparation method thereof | |
| CN101879268B (en) | Method for preparing Chinese medicinal oral liquid for treating attention deficit hyperactivity disorder | |
| CN102861201B (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN106581583A (en) | Chinese medicinal composition for treatment of chronic heart failure and preparation method thereof | |
| CN101884768B (en) | Method for preparing blood stasis-eliminating and stagnation-dissipating enema | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN103142894B (en) | Traditional Chinese medicine composition for rehabilitation of tumor patients after radiotherapy and chemotherapy, and preparation method thereof | |
| CN103251876A (en) | Traditional Chinese medicine composition used for treating chronic liver diseases | |
| CN102552861A (en) | Ginseng Sini granules and preparing method thereof | |
| CN102319401B (en) | Traditional Chinese medicine composition for tonifying qi and invigorating blood circulation, invigorating spleen and dredging collaterals | |
| CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN103040983B (en) | Traditional Chinese medicine for preventing and/or treating premonitory apoplexy and preparation method thereof | |
| CN101293059B (en) | Compound Chinese medicine for treating diabetes | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN109464607A (en) | A kind of Traditional Chinese medicinal liquor and its preparation process | |
| CN102228649B (en) | Quality control method for Shufeng Huoluo tablets | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN101190307B (en) | Traditional Chinese medicine compound preparations for treating congestive heart failure | |
| CN107669860A (en) | A kind of Chinese medicine composition and its application with blood sugar reducing function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170426 |
|
| WD01 | Invention patent application deemed withdrawn after publication |